Epitomics

Aushon Biosystems has launched Cira, its new multiplex immunoassay platform.

Bio-Rad this week introduced its V3 Western Workflow, a portfolio of products for Western blotting that include its TGX Stain-Free gels, ChemiDox MP imaging system, and TransBlot Turbo transfer system.

Epitomics has released new rabbit monoclonal antibodies for a variety of proteins including phospho LRRK2, TTF1, CHx10, and LSD1.

NanoInk this week released its new NanoArray Assay System for the automated analysis of its protein NanoArray assays.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma for mass spec workflows like SISCAPA and immuno-MALDI.

Under its contract with SAIC-Frederick, Epitomics will develop high affinity and renewable agents to capture tryptic peptides derived from human plasma protein biomarkers.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.